Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q412963> ?p ?o }
Showing triples 1 to 54 of
54
with 100 triples per page.
- Q412963 subject Q14566194.
- Q412963 subject Q7108202.
- Q412963 subject Q8625430.
- Q412963 subject Q8636420.
- Q412963 subject Q8949762.
- Q412963 subject Q8990102.
- Q412963 abstract "Cabazitaxel (previously XRP-6258, trade name Jevtana) is a semi-synthetic derivative of a natural taxoid. It was developed by Sanofi-Aventis and was approved by the U.S. FDA for the treatment of hormone-refractory prostate cancer on June 17, 2010. It is a microtubule inhibitor, and the fourth taxane to be approved as a cancer therapy.REDIRECT Template:Unreliable source?Cabazitaxel in combination with prednisone is a treatment option for hormone-refractory prostate cancer following docetaxel-based treatment.".
- Q412963 atcPrefix "L01".
- Q412963 atcSuffix "CD04".
- Q412963 casNumber "183133-96-2".
- Q412963 chEBI "63584".
- Q412963 drugbank "DB06772".
- Q412963 fdaUniiCode "51F690397J".
- Q412963 iupacName "(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4-(Acetyloxy)-15-{[(2R,3S)-3-{[(tert-butoxy)carbonyl]amino}-2-hydroxy-3-phenylpropanoyl]oxy}-1-hydroxy-9,12-dimethoxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl benzoate".
- Q412963 pubchem "9854073".
- Q412963 thumbnail Cabazitaxel.png?width=300.
- Q412963 wikiPageExternalLink dpdirect.jsp?name=Cabazitaxel.
- Q412963 wikiPageExternalLink jevtana.html.
- Q412963 wikiPageExternalLink www.jevtana.com.
- Q412963 wikiPageWikiLink Q12078.
- Q412963 wikiPageWikiLink Q1435822.
- Q412963 wikiPageWikiLink Q14566194.
- Q412963 wikiPageWikiLink Q158205.
- Q412963 wikiPageWikiLink Q181257.
- Q412963 wikiPageWikiLink Q189933.
- Q412963 wikiPageWikiLink Q204711.
- Q412963 wikiPageWikiLink Q239426.
- Q412963 wikiPageWikiLink Q420436.
- Q412963 wikiPageWikiLink Q424972.
- Q412963 wikiPageWikiLink Q425227.
- Q412963 wikiPageWikiLink Q7108202.
- Q412963 wikiPageWikiLink Q7180990.
- Q412963 wikiPageWikiLink Q7689669.
- Q412963 wikiPageWikiLink Q8625430.
- Q412963 wikiPageWikiLink Q8636420.
- Q412963 wikiPageWikiLink Q8949762.
- Q412963 wikiPageWikiLink Q8990102.
- Q412963 atcPrefix "L01".
- Q412963 atcSuffix "CD04".
- Q412963 casNumber "183133".
- Q412963 chebi "63584".
- Q412963 drugbank "DB06772".
- Q412963 iupacName "-4".
- Q412963 pubchem "9854073".
- Q412963 unii "51".
- Q412963 type ChemicalSubstance.
- Q412963 type Drug.
- Q412963 type ChemicalObject.
- Q412963 type Thing.
- Q412963 type Q8386.
- Q412963 comment "Cabazitaxel (previously XRP-6258, trade name Jevtana) is a semi-synthetic derivative of a natural taxoid. It was developed by Sanofi-Aventis and was approved by the U.S. FDA for the treatment of hormone-refractory prostate cancer on June 17, 2010.".
- Q412963 label "Cabazitaxel".
- Q412963 depiction Cabazitaxel.png.
- Q412963 homepage www.jevtana.com.